Palatin Technologies, Inc. (NYSEAMERICAN:PTN) gapped up prior to trading on Tuesday . The stock had previously closed at $1.35, but opened at $1.42. Palatin Technologies shares last traded at $1.43, with a volume of 50787 shares changing hands.
Several research analysts recently issued reports on PTN shares. TheStreet downgraded shares of Palatin Technologies from a “c-” rating to a “d” rating in a research report on Tuesday, February 19th. LADENBURG THALM/SH SH set a $3.00 price target on shares of Palatin Technologies and gave the stock a “buy” rating in a research report on Thursday, May 23rd. HC Wainwright upped their price target on shares of Palatin Technologies from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Thursday, May 9th. Finally, Zacks Investment Research upgraded shares of Palatin Technologies from a “hold” rating to a “buy” rating and set a $0.75 price target on the stock in a research report on Friday, February 15th.
Palatin Technologies (NYSEAMERICAN:PTN) last issued its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.01).
Palatin Technologies Company Profile (NYSEAMERICAN:PTN)
Palatin Technologies, Inc, a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The company's principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder.
Read More: Recession
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.